ACE and COVID-19: COVID-19 gains entry into human cells via binding ACE2, which in the context of the myocardium may lead to alterations in signaling pathways resulting in myocardial injury.10 See section below for further discussion on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in the setting of COVID-19.